A prospective clinical study based on Tumer 3D drug sensitivity test in patients with advanced lung cancer who failed in second-line chemotherapy

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-17012662

Enrollment

Unknown

Registered

2017-09-13

Start date

2017-09-13

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced lung cancer

Interventions

drug administrated group:non-intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Subject suffered from lung cancer; (2) existence of measurable lesions in patients by CT examination; (3) patients with advanced lung cancer who failed in second-line chemotherapy; (4) Ability to organize biopsy; (5) ECOG 0-1; (6) The subject or the legal representative of the subject voluntarily signed a written informed consent form; (7) Expected survival = 3 months.

Exclusion criteria

Exclusion criteria: (1) Currently participating in other clinical studies; (2) Any psychiatric or cognitive impairment, thereby limiting the subject to understand and sign the informed consent of the book; (3) Not in accordance with requirements and requirements of clinical research programs, clinical research participation; (4) Patients with a history of drug abuse or alcohol abuse; (5) Patients unwilling or unable to adopt adequate contraceptive measures during study treatment unless the patient record had undergone sterilization surgery or postmenopausal women.

Design outcomes

Primary

Measure	Time frame
Disease Control Rate;	—

Countries

China

Contacts

Public ContactBin LI

CMIC (Beijing) Pharmaceutical Services Co., Ltd.

bin-li@cmicgroup.com+86 18001363573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026